文献速递银屑病与炎症性皮肤病

银屑病系统治疗的重叠网络Meta分析概览:数量不等于质量

Overlapping network meta-analyses on psoriasis systemic treatments, an overview: quantity does not make quality.
PubMed 文献 · Br J Dermatol · 2022-04-12

该概览评估了银屑病系统治疗领域网络Meta分析(NMA)的冗余性和特征。共纳入47篇冗余NMA,仅2篇(4%)涵盖所有可用治疗,83%结果置信度极低,55%接受药企资助,所有摘要均存在spin。结论认为多数NMA方法异质、结果置信度差,临床解读需谨慎。

要点

  • 47篇NMA中仅2篇(4%)涵盖所有可用治疗,83%结果置信度极低。
  • 55%的NMA接受药企资助,40%有合同研究组织参与。
  • 仅32%考虑异质性,66%考虑一致性,所有摘要均存在spin。

核心结论

  • 该概览显示多数纳入的NMA存在重复劳动、方法异质、结果置信度差,并受报告问题和spin进一步扭曲。
  • 临床医生在寻找最可靠和全面的证据时需谨慎解读NMA。

研究设计与样本

  • 本研究为概览,检索PubMed/MEDLINE、Epistemonikos、PROSPERO及诺丁汉大学循证皮肤病学中心证据更新库至2021年2月25日。
  • 纳入标准为包含成人中重度银屑病随机对照试验的系统评价与NMA,评估系统治疗对比安慰剂或阳性对照的疗效和/或安全性。
  • 共纳入47篇冗余NMA,主要结局为每年冗余NMA数量及其重叠程度。

主要发现

  • 47篇NMA中仅2篇(4%)涵盖所有可用治疗。
  • 14篇(30%)同时评估疗效和安全性,5篇(11%)同时评估短期和长期。
  • 39篇(83%)结果置信度极低,仅10篇(21.3%)注册了方案。
  • 26篇(55%)接受药企资助,19篇(40%)有合同研究组织参与。
  • 多数NMA摘要报告质量差,所有摘要均存在spin;仅32%考虑异质性,66%考虑一致性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Network meta-analyses (NMAs) have become successful in addressing gaps in the comparative effectiveness of systemic treatments in moderate-to-severe psoriasis. However, their increasing number carries both a risk of overlap and reproducibility issues that can hamper clinical decision-making. OBJECTIVES: In this overview, we aimed to assess redundancy across these NMAs and to describe their characteristics. MATERIALS AND METHODS: We considered all systematic reviews with NMAs of randomized controlled trials that included adult patients with moderate-to-severe psoriasis and that evaluated the efficacy and/or safety of systemic treatments compared with placebo or with an active comparator. PubMed/MEDLINE, Epistemonikos, PROSPERO and the Evidence update of the Centre of Evidence-Based Dermatology of the University of Nottingham were searched up to 25 February 2021. Our main outcome was the number per year of redundant NMAs and the extent of their overlap. We also described their features, especially, the confidence in the results of the reviews, the funding of the studies and the presence of spin (a description that overstates efficacy and/or understates harm), reporting issues and methodological characteristics. RESULTS: In total, 47 redundant NMAs were included. Only two of 47 (4%) included all available treatments. Both efficacy and safety were evaluated in 14 of 47 (30%) NMAs and both short- and long-term evaluations were assessed in five of 47 (11%). Confidence in the results was critically low for 39 of 47 (83%) NMAs and only 10 of 47 (21·3%) registered a protocol. Twenty-six of 47 NMAs (55%) received pharmaceutical funding. Contract research organizations were involved in 19 of 47 (40%) NMAs. Reporting was poor across most of the NMA abstracts and spin was present in all of the abstracts. Almost half of the NMAs failed to consider important limitations such as heterogeneity (considered in 32%) or consistency (considered in 66%). CONCLUSIONS: In addition to a duplication of efforts, our overview showed heterogeneous methods and poor confidence in the results in a majority of the included NMAs, further distorted by reporting issues and spin. Clinicians need to interpret NMAs with caution when looking for the most reliable and comprehensive evidence.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Guelimi R, Afach S, Régnaux JP, et al. Overlapping network meta-analyses on psoriasis systemic treatments, an overview: quantity does not make quality. Br J Dermatol. 2022. PMID: 34854074. doi:10.1111/bjd.20908

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。